Celon Pharma SA AI Stock Analysis
Celon Pharma SA (8RP) AI Stock Analysis
Celon Pharma SA
(Frankfurt:8RP)
No summary available
Celon Pharma SA (8RP) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 189.32M
- Dividend Yield
- ―
- Average Volume (3M)
- 57
- Price to Earnings (P/E)
- 7.4
- Beta (1Y)
- 0.30
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Germany
- Employees
- 560
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Celon Pharma SA Business Overview & Revenue Model
Company Description
Celon Pharma S.A. operates as a fully-integrated pharmaceutical firm, undertaking the investigation, development, production, and distribution of diverse medicinal formulations. Its business model is structured around two principal areas: generic dru...
Celon Pharma SA Peers Comparison
Overall Rating
PL:BIO45Neutral
PL:MAB41Neutral
PL:RVU37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | PLN 297.09M | -25.18 | -1.97% | ― | -15.67% | -307.60% | |
| 41Neutral | PLN 152.57M | -2.70 | -159.09% | ― | 11.57% | 4.35% | |
| 37Underperform | PLN 390.73M | -5.61 | -139.66% | ― | -11.57% | 43.60% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:8RP | Celon Pharma SA | 3.42 | -1.45 | -29.73% | |
| PL:RVU | Ryvu Therapeutics SA | 16.90 | -7.20 | -29.88% | |
| PL:SVE | Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. | 2.67 | -1.35 | -33.58% | |
| PL:BIO | BIOTON S.A. | 3.46 | -0.46 | -11.73% | |
| PL:MOC | OncoArendi Therapeutics SA | 5.38 | -0.67 | -11.07% | |
| PL:MAB | Mabion SA | 9.44 | 1.91 | 25.38% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
